This suggests a multifaceted regulatory network where ETS1, miR-203a-3p, and miR-204-3p interact with other molecular pathways, potentially leading to enhanced tumor aggressiveness and poor clinical outcomes in PTC patients. Here, ETS1 is linked to neoplasm.